{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:45:01Z","timestamp":1769150701291,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40120-016-0051-7","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T05:17:01Z","timestamp":1473743821000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study"],"prefix":"10.1007","volume":"5","author":[{"given":"Ralf A.","family":"Linker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"51_CR1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"M Sospedra","year":"2005","unstructured":"Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683\u2013747.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"51_CR2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","volume":"3","author":"JP DiMarco","year":"2014","unstructured":"DiMarco JP, O\u2019Connor P, Cohen JA, et al. First-dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014;3(5):629\u201338.","journal-title":"Mult Scler Relat Disord."},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/DHPS.S69640","volume":"7","author":"A Gajofatto","year":"2015","unstructured":"Gajofatto A, Turatti M, Monaco S, Benedetti MD. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf. 2015;7:157\u201367.","journal-title":"Drug Healthc Patient Saf."},{"issue":"2","key":"51_CR4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","volume":"261","author":"R Gold","year":"2014","unstructured":"Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014;261(2):267\u201376.","journal-title":"J Neurol"},{"issue":"11","key":"51_CR5","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology."},{"issue":"5","key":"51_CR6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"51_CR7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","volume":"3","author":"L Kappos","year":"2014","unstructured":"Kappos L, Cohen J, Collins W, et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult Scler Relat Disord. 2014;3(4):494\u2013504.","journal-title":"Mult Scler Relat Disord."},{"issue":"5","key":"51_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401.","journal-title":"N Engl J Med"},{"issue":"10","key":"51_CR9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jcph.519","volume":"55","author":"D Paolicelli","year":"2015","unstructured":"Paolicelli D, Manni A, Direnzo V, et al. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: a postmarketing study. J Clin Pharmacol. 2015;55(10):1131\u20136.","journal-title":"J Clin Pharmacol"},{"key":"51_CR10","unstructured":"Limmroth V, Haverkamp W, Dechend R, et al. First dose effects of fingolimod: in depth electrocardiographic analysis confirms first dose observation is usually uneventful. In: EAN congress; 2016 (P12128)."},{"issue":"2","key":"51_CR11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.yjmcc.2009.10.009","volume":"48","author":"EE Egom","year":"2010","unstructured":"Egom EE, Ke Y, Musa H, et al. FTY720 prevents ischemia\/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1\/Akt signaling. J Mol Cell Cardiol. 2010;48(2):406\u201314.","journal-title":"J Mol Cell Cardiol"},{"key":"51_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2377-14-65","volume":"14","author":"A Laroni","year":"2014","unstructured":"Laroni A, Brogi D, Morra VB, et al. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol. 2014;14:65.","journal-title":"BMC Neurol."},{"issue":"1\u20132","key":"51_CR13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2012.09.009","volume":"323","author":"D Ontaneda","year":"2012","unstructured":"Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323(1\u20132):167\u201372.","journal-title":"J Neurol Sci"},{"issue":"7","key":"51_CR14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s12325-015-0230-4","volume":"32","author":"L Ordonez-Boschetti","year":"2015","unstructured":"Ordonez-Boschetti L, Rey R, Cruz A, et al. Erratum to: safety and tolerability of fingolimod in latin american patients with relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study. Adv Thery. 2015;32(7):636.","journal-title":"Adv Thery."},{"issue":"7","key":"51_CR15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12325-015-0224-2","volume":"32","author":"L Ordonez-Boschetti","year":"2015","unstructured":"Ordonez-Boschetti L, Rey R, Cruz A, et al. Safety and tolerability of fingolimod in latin american patients with relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study. Adv Thery. 2015;32(7):626\u201335.","journal-title":"Adv Thery."},{"key":"51_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40360-015-0006-0","volume":"16","author":"SP Ramseier","year":"2015","unstructured":"Ramseier SP, Roth S, Czaplinski A. A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure. BMC Pharmacol Toxicol. 2015;16:7.","journal-title":"BMC Pharmacol Toxicol."},{"key":"51_CR17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2015.10.015","volume":"289","author":"BI Yamout","year":"2015","unstructured":"Yamout BI, Zeineddine MM, Tamim H, Khoury SJ. Safety and efficacy of fingolimod in clinical practice: the experience of an academic center in the Middle East. J Neuroimmunol. 2015;289:93\u20137.","journal-title":"J Neuroimmunol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-016-0051-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:39:08Z","timestamp":1498329548000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-016-0051-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s40120-016-0051-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]}}}